Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2026 Earnings Conference Call.
Cytek Biosciences Inc. (CTKB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 9,338,010 | $41,367,384 | +49% | 0.01% |
| 2. | Hillhouse Capital Management Lei Zhang | 6,657,030 | $29,490,643 | 3.54% | |
| 3. | Topline Capital Collin Mcbirney | 6,283,450 | $27,835,684 | -12% | 7.22% |
| 4. | Royce & Associates Chuck Royce | 2,081,579 | $9,221,395 | +27% | 0.07% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 973,833 | $4,314,080 | +205% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.78 | 35,000 | $97,300.00 | 55,746 | 2025-06-02 | Filing | |
| $12.27 | 241,727 | $2,964,999.21 | 13,381,054 | 2022-03-15 | Filing | |
| $12.35 | 342,143 | $4,223,926.41 | 13,139,327 | 2022-03-14 | Filing | |
| $12.77 | 337,492 | $4,309,334.10 | 12,797,184 | 2022-03-11 | Filing | |
| $12.95 | 256,992 | $3,327,583.81 | 12,459,692 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.87 | 20,000 | $117,400.00 | 5,988,502 | 2024-04-19 | Filing | |
| $7.01 | 400 | $2,804.00 | 6,008,502 | 2024-04-09 | Filing | |
| $7.00 | 1,500 | $10,500.00 | 6,008,902 | 2024-04-09 | Filing | |
| $6.71 | 20,000 | $134,200.00 | 6,010,402 | 2024-03-19 | Filing | |
| $6.77 | 20,000 | $135,400.00 | 6,030,402 | 2024-03-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,578,643 | $42,433,388 | 0% | |
| 2. | 7,660,943 | $33,942,877 | 0.03% | |
| 3. | 4,939,597 | $21,882,415 | 0% | |
| 4. | 3,059,573 | $13,557,155 | 0% | |
| 5. | 2,616,257 | $11,589,081 | 0% |
News See All
8 Best Life Sciences Penny Stocks to Buy
On March 11, CBRE shared an analysis covering the U.S. market trends in life sciences real estate.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Tina, and I will be your conference operator today.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2025 Earnings Call Transcript
Operator: Good day, everyone, and thank you for standing by. My name is Arjarie, and I will be your conference operator today.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences Second Quarter 2025 Earnings Conference Call.
Cytek Biosciences, Inc. (CTKB): A Bull Case Theory
This stock is one of several featured in our latest research.
10 Promising SmallCap Stocks Under $1 Billion Market Cap
SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those willing to dig deeper.
Cytek Biosciences (CTKB) Faced Challenges from NIH Funding Reductions
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter.
Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System
Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking a significant leap forward in flow cytometry technology.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2025 Earnings Conference Call.
Hedge Fund Resource Center